Anchiano Therapeutics Ltd. - American Depositary Share (ANCN): Price and Financial Metrics
ANCN Price/Volume Stats
| Current price | $75.36 | 52-week high | $131.20 |
| Prev. close | $4.47 | 52-week low | $0.51 |
| Day low | $73.60 | Volume | 1,564,843 |
| Day high | $131.20 | Avg. volume | 3,145,648 |
| 50-day MA | $3.26 | Dividend yield | N/A |
| 200-day MA | $1.79 | Market Cap | 559.17M |
ANCN Stock Price Chart Interactive Chart >
Anchiano Therapeutics Ltd. - American Depositary Share (ANCN) Company Bio
Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel.
Latest ANCN News From Around the Web
Below are the latest news stories about Anchiano Therapeutics Ltd that investors may wish to consider to help them evaluate ANCN as an investment opportunity.
Anchiano shares rally 76% on Chemomab merger approval, secures $45.5M capital raiseAnchiano Therapeutics (ANCN) soars 76% after-hours as its shareholders voted to approve the contemplated merger with Chemomab and the issuance of Anchiano ADSs in connection with the pending merger.Shareholders also approved a reverse split of ANCN's common shares, expected to take effect immediately prior to the closing of the merger. The combined company is... |
ANCN Stock: 10 Things to Know as Anchiano Therapeutics Rockets HigherANCN stock is an early-stage company engaged in clinical trials for rare liver, lung and skin diseases with no FDA-approved options now. |
ANCHIANO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Anchiano Therapeutics Ltd. - ANCNFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Anchiano Therapeutics Ltd. (NasdaqGS: ANCN) with Chemomab Ltd. pursuant to which Anchiano shareholders will end up owning only approximately 10% of the combined company, prior to additional PIPE financing. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds CPAH, CATM, ANCN and GNBF Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of ANCN, JWS, GXGX, and ALSK MergersWILMINGTON, Del., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: Anchiano Therapeutics Ltd. (NASDAQ GS: ANCN) regarding possible breaches of fiduciary duties and other violations of law related to Anchiano Therapeutics’ agreement to merge with Chemomab Ltd. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-anchiano-therapeutics-ltd. Jaws Acquisition Corp. (NYSE: JWS) regarding possible breaches of fiduciary duties and other violations of law related to Jaws Acquisition’s agreement to merge with Cano Health, LLC. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-jaws-acquisition-corp. GX Acquisition Corp. (NASDAQ GS: GXGX) regarding possible breaches of fiduc... |
ANCN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | -18.51% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 23.57% |
| 2019 | N/A |
Loading social stream, please wait...